Health and Fitness Health and Fitness
Sun, February 13, 2011
Sat, February 12, 2011
Fri, February 11, 2011
[ Fri, Feb 11th 2011 ] - Market Wire
Who Wears The Finance Pants?
[ Fri, Feb 11th 2011 ] - Market Wire
Company Profile for TowerJazz

NPS Pharmaceuticals to Present at Leerink Swann Hot Topics in Therapeutics Roundtable Conference


Published on 2011-02-11 05:20:55 - Market Wire
  Print publication without navigation


BEDMINSTER, N.J.--([ BUSINESS WIRE ])--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference in New York on Thursday, February 17, 2011 at 2:20 p.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investorsa™ calendar of events page on the NPS website at [ http://www.npsp.com/events ].

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is in Phase 3 development for parenteral nutrition dependent adult short bowel syndrome and is in preclinical development for additional intestinal failure related conditions. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 3 development as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical. Additional information is available at [ http://www.npsp.com ].